MDX-2001 is under clinical development by ModeX Therapeutics and currently in Phase II for Colon Cancer. According to GlobalData, Phase II drugs for Colon Cancer have an 11% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MDX-2001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MDX-2001 overview
MDX-2001 is under development for the treatment of triple-negative breast cancer (TNBC), prostate cancer, non-small cell lung cancer, pancreatic cancer, uterine cancer, colon cancer and gastric cancer. It is a tetra-specific antibody. It is administered through intravenous route. It acts by targeting CD28 and CD3.
ModeX Therapeutics overview
ModeX Therapeutics focuses on multi-specific immunotherapies for cancer and infectious disease. ModeX Therapeutics is headquartered in Natick, Massachusetts, the US.
For a complete picture of MDX-2001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
